Atara Biotherapeutics' lead product tabelecleucel (tab-cel), in development for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), will be fast-tracked when the company files for approval in the EU.
The company plans to file a marketing authorization application (MAA) with the European Medicines Agency for the experimental immunotherapy in...








